Phase IIa Study of the Product QGC001 Compared With Placebo in Patients With Essential Hypertension

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
2QG1 is a Phase IIa study aiming to assess the blood pressure lowering effect of 4-week administration of QGC001 oral doses in patients with grade I or II essential hypertension compared to placebo, to assess the safety and tolerability, to obtain preliminary PK information for QGC001 given as multiple oral doses and to determine preliminary PD profile of QGC001 multiple oral doses on plasma and urine hormones, which will be compared to that of placebo.
Epistemonikos ID: 3b53c290dbc0533ae00b1c21dfa5a7b392757c3b
First added on: May 12, 2024